Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.
No takes yet. Share an insight, caveat, or question.
Savas et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: